New approaches to understanding p53 gene tumor mutation spectra

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 431, Issue 2, 1999, Pages 199-209

  Hollstein, Monica ^a   Hergenhahn, Manfred ^a   Yang, Qin ^a   Bartsch, Helmut ^a   Wang, Zhao Qi ^b   Hainaut, Pierre ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Carcinogenesis; Mutation spectrum; p53

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RISK; CARCINOGENESIS; COLORECTAL CANCER; ENVIRONMENTAL FACTOR; GENE DELETION; GENE SEQUENCE; GENETIC LINKAGE; HEMANGIOMA; HUMAN; LIVER CANCER; LUNG CANCER; PLASMACYTOMA; POINT MUTATION; PRIORITY JOURNAL; SKIN CANCER; TUMOR SUPPRESSOR GENE; UTERUS CANCER;

ANIMALS; DATABASES, FACTUAL; DISEASE MODELS, ANIMAL; DNA MUTATIONAL ANALYSIS; GENES, P53; GENETIC ENGINEERING; HUMANS; MICE; MUTATION; NEOPLASMS; NEOPLASMS, EXPERIMENTAL;

EID: 0033376873     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(99)00162-1     Document Type: Article

References (83)

1. Hainaut P., Hernandez T., Robinson A., Rodriguez-Tome P., Flores T., Hollstein M., Harris C.C., Montesano R. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res. 26:1998;205-213.
2. Lindahl T. Instability and decay of the primary structure of DNA. Nature. 362:1993;709-715.
3. Hussain S.P., Harris C.C. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res. 58:1998;4023-4037.
4. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:2000;81-137.
5. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 89:1997;323-331.
6. El-Deiry W.S. Regulation of p53 downstream genes. Semin. Cancer Biol. 8:1998;345-357.
7. Wang X.W., Yeh H., Schaeffer L., Roy R., Moncollin V., Egly J.M., Wang Z., Friedberg E.C., Evans M.K., Taffe B.G., Bohr V.A., Weeda G., Hoeijmakers J.H.J., Forrester K., Harris C.C. P53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet. 10:1995;188-195.
8. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Ishioka C., Friend S.H., Iggo R. Nucleic Acids Res. 22:1994;3259-3260.
9. Cho Y., Gorina S., Jeffrey P.D., Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science. 265:1994;346-355.
10. Hollstein M., Moeckel G., Hergenhahn M., Spiegelhalder B., Keil M., Werle-Schneider G., Bartsch H., Brickmann J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 405:1998;145-154.
11. Podlutsky A., Oesterholm A.-M., Hou S.-M., Hofmaier A., Lambert B. Spectrum of point mutations in the coding region of the hypoxanthine-guanine phosphoribosyl-transferase (hprt) gene in human T-lymphocytes in vivo. Carcinogenesis. 19:1998;557-566.
12. Cariello N.F. Software for the analysis of mutations at the human hprt gene. Mutat. Res. 312:1994;173-185.
13. Greenblatt M.S., Bennett W.P., Hollstein M., Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:1994;4855-4878.
14. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J., Remington L., Jacks T., Brash D.E. Sunburn and p53 in the onset of skin cancer. Nature. 372:1994;773-776.
15. Dogliotti E., Hainaut P., Hernandez T., D'Errico M., DeMarini D.M. Mutation spectra resulting from carcinogenic exposure: from model systems to cancer-related genes. Rec. Results in Cancer Res. 154:1998;97-124.
16. Holmquist G.P., Gao S. Somatic mutation theory, DNA repair rates, and the molecular epidemiology of p53 mutations. Mutat. Res. 386:1997;69-101.
17. Montesano R., Hainaut P., Wild C.P. Hepatocellular carcinoma: from gene to public health. J. Natl. Cancer Inst. 89:1997;1844-1851.
18. Denissenko M.F., Pao A., Tang M.-S., Pfeifer G.P. Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hotspots in p53. Science. 274:1996;430-432.
19. Oghaki H., Hainaut P., Hernandez T., Kleihues P. TP53 germline mutations and the Li-Fraumeni syndrome. Kleihues P., Cavenee W.K. Pathology and Genetics: Tumours of the Nervous System. 1997;IARC, Lyon.
20. Loeb L. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51:1991;3075-3079.
21. Mao E.F., Lane L., Lee J., Miller J.H. Proliferation of mutators in a cell population. J. Bacteriol. 179:1997;417-422.
22. Dumaz N., Grougard A., Sarasin A., Daya-Grosjean L. Specific UV-induced mutation spectrum in the p53 gene of skin tumors from DNA-repair-deficient xeroderma pigmentosum patients. Proc. Natl. Acad. Sci. U.S.A. 90:1993;10529-10533.
23. Strauss B.S. Hypermutability and silent mutations in human carcinogenesis. Semin. Cancer Biol. 8:1998;431-438.
24. Wallace R.W. DNA on a chip: serving up the genome for diagnostics and research. Mol. Med. Today. 1977;384-389.
25. Flaman J.M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappius P., Sappino A.P., Limacher I.M., Bron L., Benhattar J., Tada M., Van Meier E.G., Estreicher A., Iggo R.D. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc. Natl. Acad. Sci. U.S.A. 92:1995;3963-3967.
26. Moshinsky D.J., Wogan G.N. UV-induced mutagenesis of human p53 in a vector replicated in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U.S.A. 94:1997;2266-2271.
27. Inga A., Scott G., Monti P., Aprile A., Abbondandolo A., Burns P.A., Fronza G. Ultraviolet-light induced p53 mutational spectrum in yeast is indistinguishable from p53 mutations in human skin cancer. Carcinogenesis. 19:1998;741-746.
28. Epstein C.B., Attiyeh E.F., Hobson D.A., Silver A.L., Broach J.R., Levine A.J. p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. Oncogene. 16:1998;2115-2122.
29. DiComo C.J., Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene. 16:1998;2527-2539.
30. Soussi T., de Fromentel C.C., May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene. 5:1990;945-952.
31. Rajewsky K., Gu H., Kuehn R., Betz Q.A.K., Mueller W., Roes J., Schwenk F. Conditional gene targeting. J. Clin. Invest. 98:1996;600-603.
32. Rossant J., Nagy A. Genome engineering: the new mouse genetics. Nat. Med. 1:1995;592-594.
33. Keohavong P., Thilly W.G. Mutational spectrometry: a general approach for hot-spot mutations in selectable genes. Proc. Natl. Acad. Sci. U.S.A. 89:1992;4623-4627.
34. -7 by combining two genotypic selection methods, MutEx enrichment and allele-specific competititve blocker PCR. Environ. Mol. Mutagen. 32:1998;200-211.
35. Jenkins G.J., Mitchell G.I., Parry J.M. Enhanced restriction site mutation (RSM) analysis of 1,2 dimethylhydrazine-induced mutations, using endogenous p53 intron sequences. Mutagenesis. 12:1997;117-123.
36. Aguilar F., Harris C.C., Sun T., Hollstein M., Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science. 264:1994;1317-1319.
37. Liu Q., Wang Y., Crist K.A., Wang Z.Y., Lou Y.R., Huang M.T., Conney A.H., You M. Effect of green tea on p53 mutation distribution in ultraviolet B radiation-induced mouse skin tumors. Carcinogenesis. 19:1998;1257-1262.
38. Queille S., Seite S., Tison S., Medaisko C., Drougard C., Fourtanier A., Sarasin A., Daya-Grosjean L. P53 mutations in cutaneous lesions induced in the hairless mouse by a solar ultraviolet light simulator. Mol. Carcinog. 22:1998;167-174.
39. Dumaz N., van Kranen H.J., de Vries A., Berg R.J., Wester P.W., van Kreijl C.F., Sarasin A., Daya-Grosjean L., de Gruijl F.R. The role of UV-B light in skin carcinogenesis through the analysis of p53 mutations in squamous cell carcinomas of hairless mice. Carcinogenesis. 18:1997;897-904.
40. Ananthaswamy H.N., Loughlin S.M., Cox P., Evans R.L., Ullrich S.E., Kripke M.L. Sunlight and skin cancer: inhibition of p53 mutations in UV-irradiated mouse skins by sunscreens. Nat. Med. 3:1997;510-514.
41. Tong Y., Smith M.A., Tucker S.B. Chronic ultraviolet exposure-induced p53 gene alterations in Sencar mouse skin carcinogenesis model. J. Toxicol. Environ. Health. 51:1997;219-234.
42. van Kranen H.J., de Gruijl F.R., de Vries A., Sontag Y., Wester P.W., Senden H.C., Rozemuller E., van Kreijl C.F. Frequent p53 alterations but low incidence of ras mutations in UV-B-induced skin tumors of hairless mice. Carcinogenesis. 16:1995;1141-1147.
43. Wang X.J., Greenhalgh D.A., Jiang A., He D., Zhong L., Medina D., Brinkley B.R., Roop D.R. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene. 17:1998;35-45.
44. Zhang S.Y., Bauer B., Mitsunaga S., Goodrow T.L., Klein-Szanto A.J. Lack of concordant p53 mutations in some paired primary and metastatic mouse squamous cell carcinomas induced by chemical carcinogens. Mol. Carcinog. 12:1995;77-81.
45. Kanjilal S., Pierceall W.E., Cummings K.K., Kripke M.L., Ananthaswamy H.N. High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity. Cancer Res. 53:1993;2961-2964.
46. Ruggeri B., DiRado M., Zhang S.Y., Bauer B., Goodrow T., Klein-Szanto A.J. Benzo(a)pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. U.S.A. 90:1993;1013-1017.
47. Kress S., Sutter C., Strickland P.T., Mukhtar H., Schweizer J., Schwarz M. Carcinogen-specific mutational pattern in the p53 gene in ultraviolet B radiation-induced squamous cell carcinomas of mouse skin. Cancer Res. 52:1992;6400-6403.
48. Ruggeri B., Caamano J., Goodrow T., DiRado M., Bianchi A., Trono D., Conti C.J., Klein-Szanto A.J.P. Alterations of the p53 tumor suppressor gene during mouse skin tumor progression. Cancer Res. 51:1991;6615-6621.
49. Cazorla M., Hernandez L., Fernandez P.L., Fabra A., Peinado M.A., Dasenbrock C., Tillmann T., Kamino K., Campo E., Kohler M., Morawieltz G., Cardesa A., Tomatis L., Mohr U. Ki-ras gene mutations and absence of p53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. Mol. Carcinog. 21:1998;251-260.
50. Rollins L.A., Leone-Kabler S., O'Sullivan M.G., Miller M.S. Role of tumor suppressor genes in transplacental lung carcinogenesis. Mol. Carcinog. 21:1998;177-184.
51. Lumniczky K., Antal S., Unger E., Wunderlich L., Hidvegi E.J., Safrany G. Carcinogenic alterations in murine liver, lung, and uterine tumors induced by in utero exposure to ionizing radiation. Mol. Carcinog. 21:1998;100-110.
52. Horio Y., Chen A., Rice P., Roth J.A., Malkinson A.M., Schrump D.S. Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice. Mol. Carcinog. 17:1996;217-223.
53. Matzinger S.A., Crist K.A., Stoner G.D., Anderson M.W., Pereira M.A., Steele V.E., Kelloff G.J., Lubet R.A., You M. K-ras mutations in lung tumors from A/J and A/J×TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and phenethyl isothiocyanate. Carcinogenesis. 16:1995;2487-2492.
54. 6-methylguanine levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol. Carcinog. 8:1993;177-185.
55. Hegi M.E., Söderkvist P., Foley J.F., Schoonhoven R., Swenberg J.A., Kari F., Maronpot R., Anderson M.W., Wiseman R.W. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis. 14:1993;803-810.
56. Chen B., Liu L., Castonguay A., Maronpot R.R., Anderson M.W., You M. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced mouse lung tumors. Carcinogenesis. 14:1993;1603-1608.
57. Goodrow T.L., Storer R.D., Leander K.R., Prahalada S.R., van Zwieten M.J., Bradley M.O. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol. Carcinogenesis. 5:1992;9-15.
58. Gressani K.M., Rollins L.A., Leone-Kabler S., Cline J.M., Miller M.S. Induction of mutations in Ki-ras and INK4a in liver tumors of mice exposed in utero to 3-methylcholanthrene. Carcinogenesis. 19:1998;1045-1052.
59. Sipowicz M.A., Weghorst C.M., Shiao Y.H., Buzard G.S., Calvert R.J., Anver M.R., Anderson L.M., Rice J.M. Lack of p53 and ras mutations in Helicobacter hepaticus-induced liver tumors in A/JCr mice. Carcinogenesis. 18:1997;233-236.
60. Calvert R.J., Tashiro Y., Buzard G.S., Diwan B.A., Weghorst C.M. Lack of p53 point mutations in chemically induced mouse hepatoblastomas: an end-stage, highly malignant hepatocellular tumor. Cancer Lett. 95:1995;175-180.
61. Rumsby P.C., Davies M.J., Evans J.G. Screening for p53 mutations in C3H/He mouse liver tumors derived spontaneously or induced with diethylnitrosamine or phenobarbitone. Mol. Carcinog. 9:1994;71-75.
62. Kress S., König J., Schweizer J., Löhrke H., Bauer-Hofmann R., Schwarz M. P53 mutations are absent from carcinogen-induced mouse liver tumors but occur in cell lines established from these tumors. Mol. Carcinog. 6:1992;148-158.
63. Furihata C., Tatematsu M., Saito M., Ishida S., Nakanishi H., Inada K., Tei H., Hattori M., Ito T., Sakaki Y. Rare occurrence of ras and p53 gene mutations in mouse stomach tumors induced by N-methyl-N-nitrosourea. Jpn. J. Cancer Res. 88:1997;363-368.
64. Ushijima T., Makino H., Okonogi H., Hosoya Y., Sugimura T., Nagao M. Mutation, loss of heterozygosity, and recombination of the p53 gene in mouse forestomach tumors induced by 2-amino-3,4-dimethylimidazo(4,5-f)quinoline. Mol. Carcinog. 12:1995;23-30.
65. Ohgaki H., Hasegawa H., Suenaga M., Kato T., Sato S., Takayama S., Sugimura T. Induction of hepatocellular carcinoma and highly metastatic squamous cell Carcinomas in the forestomach of mice by feeding 2-amino-3,4-dimethyl-Imidazo(4,5-f)quinoline. Carcinogenesis. 7:1986;1889-1893.
66. Morimura K., Yamamoto S., Murai T., Mori S., Chen T.X., Wanibuchi H., Fukushima S. LOH and mutational analysis of p53 alleles in mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxylbutyl)nitrosamine. Carcinogenesis. 20:1999;715-718.
67. Yamamoto S., Min W., Lee C.C., Salim E.I., Wanibuchi H., Sukata T., Fukushima S. Enhancement of urinary bladder carcinogenesis in nullizygous p53-deficient mice by N-butyl-N-(4-hydroxylbutyl)nitrosamine. Cancer Lett. 135:1999;137-144.
68. 6-methylguanine formation as a significant mutational factor in mouse urinary bladder carcinogenesis models. Teratog., Carcinog., Mutagen. 18:1998;101-110. quoted from Medline Abstracts.
69. Yamamoto S., Tatematsu M., Yamamoto M., Fukami H., Fukushima S. Clonal analysis of urothelial carcinomas in C3H/HeN↔BALB/c chimeric mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis. 19:1998;855-860.
70. Ogawa K., Uzvolgyi E., St. John M.K., de Oliveira M.L., Arnold L., Cohen S.M. Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in B6D2F1 mice. Mol. Carcinog. 21:1998;70-79.
71. Ozaki K., Sukata T., Yamamoto S., Uwagawa S., Seki T., Kawasaki H., Yoshitake A., Wanibuchi H., Koide A., Mori Y., Fukushima S. High susceptibility of p53(+/-) knockout mice in N-butyl-N-(4-hydroxybutyl)nitrosamine urinary bladder carcinogenesis and lack of frequent mutation in residual allele. Cancer Res. 58:1998;3806-3811.
72. Yamamoto S., Chen T., Murai T., Mori S., Morimura K., Oohara T., Makino S., Tatematsu M., Wanibuchi H., Fukushima S. Genetic instability and p53 mutations in metastatic foci of mouse urinary bladder carcinomas induced by N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis. 18:1997;1877-1882.
73. Yamamoto S., Masui T., Murai T., Mori S., Oohara T., Makino S., Fukushima S., Tatematsu M. Frequent mutations of the p53 gene and infrequent H- and K-ras mutations in urinary bladder carcinomas of NON/Shi mice treated with N-butyl-N-(4-hydroxybutyl)nitrosamine. Carcinogenesis. 16:1995;2363-2368.
74. Jerry D.J., Butel J.S., Donehower L.A., Paulsen E.J., Cochran C., Wiseman R.W., Medina D. Infrequent p53 mutations in 7,12-dimethylbenz(a)anthracene-induced mammary tumors in BALB/c and p53 hemizygous mice. Mol. Carcinog. 9:1994;175-183.
75. Murase T., Niwa K., Morishita S., Itoh N., Mori H., Tanaka T., Tamaya T. Rare occurrence of p53 and ras gene mutations in preneoplastic and neoplastic mouse endometrial lesions induced by N-methyl-N-nitrosourea and 17 beta-estradiol. Cancer Lett. 92:1995;223-227.
76. Trukhanova L.S., Hong H.-H.L., Sills R.C., Bowser A.D., Gaul B., Boorman G.A., Turusov V.S., Devereux T.R., Dixon D. Predominant p53 G→A transition mutation and enhanced cell proliferation in uterine sarcomas of CBA mice treated with 1,2-dimethylhydrazine. Toxicol. Pathol. 26:1998;367-374.
77. Okamoto M., Ohtsu H., Kominami R., Yonekawa H. Mutational and LOH analyses of p53 alleles in colon tumors induced by 1,2-dimethylhydrazine in F1 hybrid mice. Carcinogenesis. 16:1995;2659-2666.
78. Saez G.T., Oliva M.R., Mangues R., Pellicer A. Absence of MDM-2 gene amplification in experimentally induced tumors regardless of p53 status. Mol. Carcinog. 9:1994;40-45.
79. Brathwaite O., Bayona W., Newcomb E.W. P53 mutations in C57BL/6 murine thymic lymphomas induced by γ-irradiation and N-methylnitrosourea. Cancer Res. 52:1992;3791-3795.
80. Gutierrez M.I., Bhatia K., Siwarski D., Wolff L., Magrath I.T., Mushinski J.F., Huppi K. Infrequent p53 mutation in mouse tumors with deregulated myc. Cancer Res. 52:1992;1032-1035.
81. Duddy S.K., Parker R.F., Bleavins M.R., Gough A.W., Rowse P.E., Gorospe S., Dethloff L.A., de la Iglesia F.A. P53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione Troglitazone. Toxicol. Appl. Pharmacol. 156:1999;106-112. quoted from Medline.
82. Shimokado K., Watanabe H., Sumii M., Miyagawa K., Kamiya K., Dohi K., Niwa O. P53 gene mutation and loss of heterozygosity of chromosome 11 in methylcholanthrene-induced mouse sarcomas. Jpn. J. Cancer Res. 89:1998;269-277.
83. Jacks T. Lessons from the p53 mutant mouse. J. Cancer Res. Clin. Oncol. 122:1996;319-327.